Goodrich Amy
Johns Hopkins University, Kimmel Cancer Center, Baltimore, MD, USA.
Clin J Oncol Nurs. 2007 Feb;11(1 Suppl):23-36. doi: 10.1188/07.CJON.S1.23-36.
B-cell disorders include a large group of malignant and nonmalignant diseases with tremendous variation in incidence, natural history, treatment, and prognosis. This article will focus on adult idiopathic thrombocytopenic purpura (ITP) and chronic lymphocytic leukemia (CLL). Clinicians must individualize treatment for ITP and CLL to each patient. Observation without intervention is appropriate for some patients, whereas immediate treatment is indicated for others. Deciding when to treat and which agents to use can be difficult, but new therapeutic options are emerging for both conditions.
B细胞疾病包括一大类恶性和非恶性疾病，其发病率、自然病程、治疗方法和预后差异极大。本文将重点关注成人特发性血小板减少性紫癜（ITP）和慢性淋巴细胞白血病（CLL）。临床医生必须针对每位ITP和CLL患者制定个体化治疗方案。对于一些患者，观察而不进行干预是合适的，而对于另一些患者则需要立即治疗。决定何时治疗以及使用何种药物可能很困难，但这两种疾病都有新的治疗选择正在出现。
